Another Alzheimer’s drug candidate suffers setback
It’s not been a good couple of years for Alzheimer’s research. Recently, Baxter’s Gammagard joined J&J and Pfizer’s iv bapineuzumab and Eli Lilly’s solanezumab in [...]
New in Drug Safety
/ By Tim / Clinical Trials, Drug Safety, Featured on app / 0 comments
It’s not been a good couple of years for Alzheimer’s research. Recently, Baxter’s Gammagard joined J&J and Pfizer’s iv bapineuzumab and Eli Lilly’s solanezumab in [...]
More in Drug Safety
/ By Kerry / Drug Safety / 1 comment
/ By Kerry / Drug Safety / 1 comment
/ By Tim / Drug Safety, Featured on app / 0 comments
/ By Tim / Drug Safety, Featured on app / 0 comments
/ By Tim / Drug Safety, Featured on app / 0 comments
/ By Tim / Drug Safety, Featured on app / 0 comments
/ By jolene / Drug Discovery, Drug Safety, Market Access, Orphan Drugs / 0 comments
/ By Tim / Drug Safety, Featured on app / 0 comments
/ By Kerry / Drug Safety / 0 comments
/ By Tim / Drug Safety, Featured on app / 0 comments
